November 07 - 10, 2017  ·  Matrix building
SALAS-SVA Conference 2017 (SALAS)
Joint SALAS -SVA Conference 2017




7-8 November will be a 2 day SVA conference

9-10 November will be a 2 day SALAS conference

The theme of this year's SALAS conference is The Future of Lab Animal Facility (9th Nov) and Animal Modelling & the Future ahead.(10th Nov)



 

 

4 Days

(7-8 Nov:SVA conference, 9-10 Nov: SALAS conference)

2 Days

(9-10 November SALAS conference)

1 Day

Early Bird Registration

(Till 1st Oct 2017)

SALAS Members

$350

$250

 

-

Non-SALAS Members

$450

$350

Students

$300

$200

 

 

Normal Registration

SALAS Members

$400

$300

$160

Non-SALAS Members

$500

$400

$210

Students

$450

$250

$135

AGENDA
Tuesday, November 7
9:00 AM
Event Start
9:00 AM - 6:00 PM
SVA Conference
Wednesday, November 8
9:00 AM - 6:00 PM
SVA Conference
Thursday, November 9
8:30 AM - 5:30 PM
SALAS conference
9:05 AM - 9:55 AM
Additive Manufacturing and Animal Research
Additive manufacturing has been widely talked about in recent years. Some people praised the technology, and some doubted it. What exactly is additive manufacturing? What are the pros and cons? How can this technology help in research involving animals?
9:55 AM - 10:45 AM
Automated solutions inside the wash rooms - Robotics
Automated solutions inside the wash rooms : benefits for people, organization and for a rewardable research Analyses of the interconnections between automated equipment and facility flows, with focus on case studies coming from worldwide experiences and the way to justify the investment.
11:15 AM - 12:05 PM
NACLAR Updates
The talk will give the background to the setting up of NACLAR, and will cover the drafting and publication of the NACLAR Guidelines. The issues and challenges in the implementation and revision of the Guidelines will also be discussed.
12:05 PM - 12:55 PM
Digital Pathology in Veterinary Diagnostics and Biomedical Research
Advancement of digital technology and global connectivity has given rise to telemedicine and telepathology in both human and veterinary fields. While technical basis of histopathology has changed little since 19th century and is still fundamental, digital pathology has already been integrated into veterinary colleges, hospitals and diagnostic laboratories. Automated slide image analysis and artificial intelligence have been used in biomedical research. Further advancement of such technologies is inevitable. Traditional gross pathology and light microscopy will change, and these will affect the way clinicians, pathologists and researchers visualize, analyze and share their cases. It is crucial to learn and adapt to these advancements in the current era of digitization.
2:00 PM - 2:50 PM
3D Bioprinting Applications for Pharmaceutical and Biotechnology
3D Printing and bioprinting is a fast growing field that is creating great impact on the future of healthcare. The field is fuelled by innovations in materials, processes and received a strong boost with the advent of bioprinting technique. 3D Bioprinting aims to produce engineered tissue in a repeatable, reconfigurable, and optimized manner. In this talk, we will present our experiences in printing of scaffolds for tissue engineering and cell-encapsulated hydrogels. Various examples will be shown to illustrate the potential of this technology in toxicology testing and lab animal sciences.
Friday, November 10
8:30 AM - 5:30 PM
SALAS conference
9:50 AM - 10:40 AM
Alternative methods for the efficient and accurate prediction of organ-specific toxicity
11:10 AM - 12:00 PM
Using the Social Amoeba Dictyostelium as a biomedical model: An innovative approach to help children with intractable epilepsy
Brief Abstract: Epilepsy is a severe neurological disorder where 30% of patients continue to experience seizures despite treatment, with research predominantly involving animals. We have developed a replacement model for this research, the social amoeba Dictyostelium discoideum, to discover a mechanism of action for a common anti-epileptic drug. This enabled us to identify more potent compounds including a fat, found in coconuts, that is used in a dietary treatment for drug-resistant epilepsy. From this, we have demonstrated that the compound rapidly blocks seizure activity, and have developed an improved diet for children with drug resistant epilepsy that is currently in clinical trials. Full Abstract: Our research has focused on employing the social amoeba Dictyostelium as a simple model system for biomedical research. The model provides a range of advantages in this role including rapid growth, single and multiple cell stages, well characterised development, rapid genetic ablation or protein tagging and the use of isogenic cultures. Here we will outline a long-standing research area in our laboratory concerning epilepsy, initiated in Dictyostelium and translated to mammalian systems. Our studies initial employed Dictyostelium to better understand the molecular mechanisms of the commonly used epilepsy treatment, valproic acid. We showed that, in Dictyostelium, the drug blocked turnover of phosphoinositides, and were able to show a similar effect in the mammalian brain during seizure progression. Using this effect in Dictyostelium, we then identified a range of compounds with enhanced activity. One of these compounds, decanoic acid, is a major constituent of a diet used to treat drug resistant epilepsy, called the medium chain triglyceride (MCT) ketogenic diet. We then showed that decanoic acid, which is elevated in the plasma of patients on the diet, acts to directly control seizure activity in multiple seizure models, and this effect is not shown for ketones, suggesting that the diet may not act via ketogenesis. We further identified a primary target for decanoic acid, in this therapeutic role. From this work, clinical trials are now underway for the treatment of both children and adults with intractable epilepsy using a new ketogenic diet derived from this work. This projects therefore highlights the use of Dictyostelium as a simple and malleable model system for biomedical research, and successful translation to clinical studies.
12:00 PM - 12:50 PM
Uncommon Laboratory Animal Species
This talk is designed to give an introduction to some uncommon species seen in laboratory animal medicine. The talk focuses on model information, care and diseases of the unique animals. Major emphasis is placed upon spontaneous diseases arising in these species. Animal models to be discussed include: Electric eels, tentacled snakes, galagos (bush babies), Xenopus laevis, zebra finches, Grasshopper Mice (Onychmys torridus), terrestrial frogs, naked mole rats (Heterocephalus glaber), etc…
2:00 PM - 2:50 PM
The use of ferrets as an animal model in virology with a focus on virus transmission studies
The ferret belongs to the family of mustelids (weasels) and the infection of ferrets with influenza viruses has been described as early as 1933. To this day, the ferret remains an important animal model to mimic human infection by several respiratory viruses including influenza viruses, coronaviruses and Respiratory Syncytial Virus. An important feature of respiratory viruses is their ability to transmit via the air between individuals. This key aspect can be studied in custom designed ‘airborne transmission settings’ equipped with ferrets as virus donors and recipients. General aspects, advantages and limitations of the ferret in virological research will be discussed.
2:50 PM - 3:40 PM
Amoeba Tastes Bitter - A novel non-animal model for bitterness research
Brief abstract Many current medicines taste bitter, leading to low patient compliance and reduced therapeutic efficacy. Assessment of bitter taste effects of new medicines employs animal in vivo experiments that are time consuming and have limited throughput. We have investigated the replacement of animals in these tests with the amoeba Dictyostelium discoideum to show that cell behaviour is sensitive to bitter tasting compounds. Analysing of a range of structurally distinct bitter tastants using Dictyostelium, and comparing effects with responses in animal and human tests, suggests that Dictyostelium provides a useful replacement model for the prediction of bitter taste effects of new medicines. Full abstract A large number of therapeutically active compounds have a bitter taste. This often causes an aversive reaction - particularly in children - leading to decreased patient compliance and in some cases to severe reactions such as, nausea and vomiting. Identification of bitter taste liability during drug discovery utilises the rat in vivo brief access taste aversion (BATA) test which is time consuming and has limited throughput. Here, we investigate the suitability of using a simple non-animal model, the amoeba Dictyostelium discoideum, to examine taste-related responses and particularly to identify those molecules with a bitter taste liability. We initially analysed the acute effects of taste-related compounds on Dictyostelium cell behaviour to show no response to salty or sour conditions, or umami and sweet tasting compounds, whereas cells rapidly responded to bitter tastants. We then developed a medium-throughput assay, based in Dictyostelium, to monitor responses to a wide range of structurally diverse bitter tastants and a panel of blinded molecules. This assay employed visualising cells pre- and post-bitter tastant exposure, recording cell response with time-lapse photography and using computer-generated quantification to monitor changes in cell membrane movement. Dictyostelium showed varying responses to the bitter tastants, with IC50 values providing a rank order of potency. Comparison of Dictyostelium IC50 values to responses observed at a similar concentration range in the rat BATA test showed a significant positive correlation between the two models (p = 0.0172). In addition, the data showed a similar response of Dictyostelium to that provided by a human sensory panel assessment test. These experiments suggest that Dictyostelium may provide a suitable model for early prediction of bitterness for novel tastants and drugs, where a common response to bitter tastants appears to be conserved from a single-celled amoebae to humans.
5:30 PM
Event End
LOCATION
Matrix building - 30 Biopolis Street Singapore Singapore 138671 Singapore 138671 Singapore

Direct Bank Transfer - to OCBC Account 552-712226-001

Account name: SINGAPORE ASSOCIATION FOR LABORATORY ANIMAL SCIENCE

 

Please email  Ocampo Ervin Marquez  (lacoem@nus.edu.sg) after the transfer to indicate that the payment is for 2017 SALAS Conference, number of attendees, number of days attending, and whether payment is for member/non-member/student.

Cheque – made payable to:  SINGAPORE ASSOCIATION FOR LABORATORY ANIMAL SCIENCE

Please mail to the following address:

Singapore Association For Laboratory Animal Science

Ghim Moh Estate Post Office PO Box 047

Singapore 912732

Indicate on the cheque that the payment is for 2017 SALAS Conference, number of attendees,

number of days attending, and whether payment is for member/non-

member/student.

CASH will not be accepted at Onsite registration